Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Nat Rev Clin Oncol. 2020 Jun 8;17(9):569–587. doi: 10.1038/s41571-020-0377-z

Figure 2. Targeted therapy for MET amplification.

Figure 2.

In six prospective phase I/II clinical trials, patients with cancers possessing higher levels of MET amplification or gene copy number derived increased benefit from MET-directed targeted therapy. Trials included patients with non-small cell lung cancer (NSCLC), papillary renal cell cancer (PRCC), and other solid tumors. While cutoffs for MET amplification/gene copy number varied, the cutoff of a MET/CEP7 ratio or MET gene copy number of 4 was chosen for consistency for trials that used FISH; patient-level data were reviewed to calculate response rates. For the only trial which employed next-generation sequencing (NGS), the trial cutoff of MET gene copy number ≥6 was used. The objective response rate is depicted by cancers that fall below these cutoffs (light red circles) and cancers that met or exceeded these cutoffs (red circles). The size of each circle represents the size of the subpopulation within each trial (with the smallest circle representing an n of 2), and each row represents a single trial. §MET amplification was determined by FISH. ǂMET amplification was determined by NGS.